Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Zirkelbach JF, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N. Barbato MI, et al. Among authors: pan l. Clin Cancer Res. 2024 Aug 15;30(16):3364-3370. doi: 10.1158/1078-0432.CCR-24-0949. Clin Cancer Res. 2024. PMID: 38875108
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, Goheer MA, Helms WS, Pan L, Xu Y, Fan J, Leong R, Liu J, Yang Y, Windsor K, Ou M, Stephens O, Oh B, Reaman GH, Nair A, Shord SS, Bhatnagar V, Daniels SR, Sickafuse S, Goldberg KB, Theoret MR, Pazdur R, Singh H. Casey D, et al. Among authors: pan l. Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12. Clin Cancer Res. 2021. PMID: 33712511
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, Zirkelbach JF, Pan Y, Liu J, Aungst SL, Miller CP, Shah M, Rahman NA, Theoret M, Kluetz P, Pazdur R, Beaver JA, Singh H. Mehta GU, et al. Among authors: pan l, pan y. Oncologist. 2024 Aug 5;29(8):667-671. doi: 10.1093/oncolo/oyae151. Oncologist. 2024. PMID: 38970465 Free PMC article. Clinical Trial.
FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.
Agrawal S, Lee C, Pierce WF, Everhart E, King-Ducre A, Royce M, Osgood CL, Amiri-Kordestani L, Chiu HJ, Ricks TK, Pan L, Fourie Zirkelbach J, Charlab R, Pacanowski M, Kim T, Pazdur R, Kluetz PG, Gao JJ. Agrawal S, et al. Among authors: pan l. Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-1708. Online ahead of print. Clin Cancer Res. 2024. PMID: 39377782
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Woods AC, Norsworthy KJ, Choe M, Gehrke BJ, Chen H, Vallejo J, Pan L, Jiang X, Li H, Kraft J, Liu J, Charlab R, Okusanya OO, Booth B, Pazdur R, Theoret MR, de Claro RA. Woods AC, et al. Among authors: pan l. Clin Cancer Res. 2024 Oct 30. doi: 10.1158/1078-0432.CCR-24-2196. Online ahead of print. Clin Cancer Res. 2024. PMID: 39475462
8,455 results